|
WO2019106043A1
|
|
Pharmaceutical composition comprising obeticholic acid
|
|
WO2018153977A1
|
|
Stable composition of tenofovir alafenamide
|
|
US2019389847A1
|
|
Crystalline Brexpiprazole
|
|
US2020055923A1
|
|
Antibody Preparation
|
|
WO2018065348A1
|
|
Novel enteric-coated tablet comprising vortioxetine
|
|
US2020069593A1
|
|
Immediate Release Tablet of a Benzothiophene Compound
|
|
WO2018033484A1
|
|
Pharmaceutical compositions of a benzothiophene compound
|
|
CN109415426A
|
|
The glycoprotein of acetyl rate with reduced sialic acid residues
|
|
EP3411370A1
|
|
Anhydrate-free polymorphically pure micronized crystalline brexpiprazole dihydrate for use in intramuscular injectable sustained release formulations
|
|
EP3335702A1
|
|
Pharmaceutical compositions comprising omarigliptin
|
|
EP3335704A1
|
|
Pharmaceutical composition comprising omarigliptin
|
|
EP3335703A1
|
|
Pharmaceutical composition comprising omarigliptin
|
|
EP3335701A1
|
|
Pharmaceutical composition comprising omarigliptin
|
|
WO2017072264A1
|
|
Solid composition comprising suvorexant
|
|
CN108174596A
|
|
Include 8- [(3R) -3- amino -1- piperidyls] -7- (2- butine -1- bases) -3, the pharmaceutical composition of 7- dihydro -3- methyl-1s-[4- methyl -2- quinazolyls) methyl] -1H- purine -2,6- diketone or its pharmaceutically acceptable salt
|
|
EP3293196A1
|
|
Process for purifying obeticholic acid
|
|
WO2017001499A1
|
|
Liquid composition comprising suvorexant
|
|
EP3196646A1
|
|
Methods of mapping protein variants
|
|
EP3184104A1
|
|
Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
|
|
EP3184102A1
|
|
Pharmaceutical composition of vortioxetine hydrobromide comprising an inert core formed of an acidic reacting compound
|
